ASH 2023 | RADAR: guiding treatment for NDMM with MRD and genetic risk
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the RADAR trial (ISRCTN46841867; UK-MRA Myeloma XV), which is currently recruiting patients across 80 sites in the UK with newly diagnosed multiple myeloma (NDMM). The trial aims to investigate response-adapted post-transplant treatment strategies using measurable residual disease (MRD) and genetic profiling as prognostic tools, providing tailored treatment for higher-risk patients. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
RADAR trial recruits patients with the newly diagnosed myeloma who are transplant eligible across 80 sites in the UK. We have now recruited close to half the required number of participants within this trial. We’ve been extremely energized by the fact that this was the first trial which was looking at both risk, which is genetic risk, and response adaption within a live trial, and we were able to, in this national trial, capture this information in over 90% of patients, both genetic risk at diagnosis, as well as able to get a minimal residual disease test done both at baseline to identify the clone and later after transplant in these patients...
RADAR trial recruits patients with the newly diagnosed myeloma who are transplant eligible across 80 sites in the UK. We have now recruited close to half the required number of participants within this trial. We’ve been extremely energized by the fact that this was the first trial which was looking at both risk, which is genetic risk, and response adaption within a live trial, and we were able to, in this national trial, capture this information in over 90% of patients, both genetic risk at diagnosis, as well as able to get a minimal residual disease test done both at baseline to identify the clone and later after transplant in these patients.
This trial is recruiting quite well, and we have currently some plans to bring in a newer treatment into the high-risk arm of the study. The high-risk arm in this particular study is defined by having more than one high-risk feature, which has been accepted by the International Myeloma Working Group, and therefore this is now being called as double hit or ultra high-risk in different studies. And therefore offering these patients a differentiated treatment is a unique feature of this particular study. And these patients are getting robust consolidation and maintenance treatment, which has been shown, at least in Phase II trials, to improve the outcomes for these patients. So we’re excited to continue to recruit into this study, and we’re hoping to share results in the form of a MRD negativity in a year or two’s time, and some results from the early, high risk randomized patients.
Read more...
Disclosures
Sanofi: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Adaptive Biotech: Honoraria, Membership on an entity’s Board of Directors or advisory committees; GSK: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Menarini Stemline: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Recordati: Honoraria; BMS ( Celgene): Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Amgen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Janssen: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
